Plain-English translation of NCT05990465 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is the first study to see if , a daily oral medication, works well and safely when combined with LV20.19 CAR T-cells—a type of cell therapy where your immune cells are modified to fight cancer. Researchers want to understand whether using these two treatments together is better than using either one alone for blood cancers that have come back or stopped responding to previous therapies.
Many patients with relapsed or refractory blood cancers have limited options after standard treatments fail. This medication has shown a good safety profile as a single agent, and combining it with cell therapy may help more patients respond to treatment.
You likely qualify if…
You likely don't qualify if…
You would take as a daily oral pill while also receiving LV20.19 CAR T-cells, which are administered through an IV injection (the cells can be fresh or thawed from storage). You would need to attend visits for monitoring, blood tests, and scans to see how your body is responding to the combination treatment. The trial is designed to enroll 12 patients and is currently recruiting at the Medical College of Wisconsin.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States